Novartis Boosts Oncology With GSK Assets; Goal Is “Preferential Access”
This article was originally published in The Pink Sheet Daily
Surprise acquisition of GSK’s marketed oncology products accompanies joint venture on OTC/consumer health; less surprising deals include divesting its animal health business to Lilly and its vaccines business (but not flu vaccines) to GSK.
You may also be interested in...
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.
Copenhagen-based start-up IO Biotech has raised a hefty €127m from a group of VC investors to accelerate its IDO- and PD-L1 targeted immuno-oncology approaches to the treatment of cancer.
Roche’s first-in-class one-dose antiviral Xofluza has been approved for marketing in the EU to treat influenza in patients aged 12 years or over, and for post-exposure prophylaxis.